贝伐单抗
医学
白质脑病
磁共振成像
疾病
芬戈莫德
儿科
神经影像学
放射科
病理
外科
多发性硬化
化疗
精神科
作者
Elena Scaffei,Bianca Buchignani,Rosa Pasquariello,Paola Cristofani,Raffaello Canapicchi,Laura Biagi,Flavio Giordano,Emanuela De Marco,Yanick J. Crow,Roberta Battini
标识
DOI:10.3389/fneur.2023.1245014
摘要
Leukoencephalopathy with Calcifications and Cysts (LCC) is a rare genetic microangiopathy exclusively affecting the central nervous system caused by biallelic mutations in SNORD118. Brain magnetic resonance imaging (MRI) is often diagnostic due to the highly characteristic triad of leukoencephalopathy, intracranial calcifications, and brain cysts. Age at onset, presentation and disease evolution can all vary, ranging from pauci-symptomatic disease to rapid evolution of signs with loss of motor and cognitive abilities. No specific therapies for LCC are currently licensed. According to the literature, bevacizumab might represent an effective modality to improve the clinical and MRI features of the disease. However, uncertainty remains as to the true efficacy of this approach, when to begin therapy, appropriate dosing, and the consequences of drug withdrawal. According to CARE guidelines, we describe the long-term clinical and neuro-radiological follow-up of a 10-year-old child with LCC. We report disease evolution following repeated cycles of treatment with bevacizumab. Our case report suggests that repeated cycles of bevacizumab might effectively modify disease progression, possibly indicating a time-dependent effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI